We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.1%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.9B
AUM Growth
+$737M
Cap. Flow
-$219M
Cap. Flow %
-1.29%
Top 10 Hldgs %
56.42%
Holding
122
New
26
Increased
36
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$353M
2
EQIX icon
Equinix
EQIX
+$266M
3
BKNG icon
Booking.com
BKNG
+$252M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$203M
5
AABA
Altaba Inc
AABA
+$162M

Top Sells

Rank Stock Value
1
KDP icon
Keurig Dr Pepper
KDP
+$596M
2
XL
XL Group Ltd.
XL
+$407M
3
LOGM
LogMein, Inc.
LOGM
+$214M
4
GILD icon
Gilead Sciences
GILD
+$207M
5
IQV icon
IQVIA
IQV
+$126M

Sector Composition

Rank Sector Weight
1 Healthcare 24.46%
2 Technology 17.58%
3 Communication Services 13.12%
4 Financials 12.19%
5 Industrials 9.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
76
DELISTED
ChemoCentryx, Inc.
CCXI
$14.5M 0.09%
1,150,000
– –
SLDB icon
77
Solid Biosciences
SLDB
$997M
$13.9M 0.08%
+19,667
New +$12.4M
ORBK
78
DELISTED
Orbotech Ltd
ORBK
$13.7M 0.08%
+230,000
New +$14.4M
DVAX
79
DELISTED
Dynavax Technologies
DVAX
$13.3M 0.08%
1,070,000
-370,000
-26% -$5.01M
BLCM
80
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$13.2M 0.08%
213,663
+13,663
+7% +$925K
CHRS icon
81
Coherus Oncology
CHRS
$219M
$11.6M 0.07%
700,000
-145,000
-17% -$2.57M
ASMB icon
82
Assembly Biosciences
ASMB
$700M
$11.1M 0.07%
+25,000
New +$11.7M
BMS
83
DELISTED
Bemis
BMS
$10M 0.06%
206,660
-235,840
-53% -$11.1M
VOYA icon
84
Voya Financial
VOYA
$8.86B
$9.19M 0.05%
185,000
– –
FATE icon
85
Fate Therapeutics
FATE
$279M
$8.63M 0.05%
+530,000
New +$6.27M
ECYT
86
DELISTED
Endocyte, Inc. Common Stock
ECYT
$7.1M 0.04%
+400,000
New +$6.87M
ITCI
87
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.42M 0.03%
+250,000
New +$5.23M
TBIO
88
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.5M 0.03%
450,000
+50,000
+13% +$582K
KALV
89
DELISTED
KalVista Pharmaceuticals
KALV
$4.42M 0.03%
+200,000
New +$2.7M
SPPI
90
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$4.2M 0.02%
250,000
+200,000
+400% +$4.33M
CRNX icon
91
Crinetics Pharmaceuticals
CRNX
$8.99B
$4.06M 0.02%
+141,815
New +$4.21M
GCVRZ
92
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.82M 0.02%
6,827,805
– –
PRNB
93
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$3.65M 0.02%
+125,000
New +$3.53M
YMAB
94
DELISTED
Y-mAbs Therapeutics
YMAB
$3.32M 0.02%
+125,000
New +$3.18M
PFNX
95
DELISTED
Pfenex Inc.
PFNX
$3.07M 0.02%
600,000
– –
ARQL
96
DELISTED
Arqule Inc
ARQL
$2.83M 0.02%
+500,000
New +$2.84M
VTAK icon
97
Catheter Precision
VTAK
$755K
$2.73M 0.02%
+1
New +$4.54M
STRO icon
98
Sutro Biopharma
STRO
$349M
$2.25M 0.01%
+15,000
New +$2.27M
TYME
99
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$1.13M 0.01%
405,857
-542,533
-57% -$1.41M
AKRX
100
DELISTED
Akorn Inc
AKRX
$909K 0.01%
70,000
-370,000
-84% -$6.08M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2018 Portfolio in Review

As of Q3 2018, Thomas Steyer held 122 positions worth $16.9B, up 4.6% from $16.2B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Thomas Steyer's Q3 2018 filing shows 26 new, 36 increased, 29 reduced and 20 closed positions. Its largest new stake was Equinix: 608,600 shares worth $263M. The largest sale was Keurig Dr Pepper, an estimated $596M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 21% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q3 2018 buy was Equinix: 608,600 shares worth $263M.
  • Thomas Steyer added most to Express Scripts Holding Company in Q3 2018, an estimated $353M increase.
  • Thomas Steyer's biggest Q3 2018 reduction was IQVIA, cutting an estimated $126M.
  • Thomas Steyer fully exited Keurig Dr Pepper in Q3 2018, selling an estimated $596M.
  • Thomas Steyer's ten largest holdings make up 56% of its $16.9B portfolio in Q3 2018.
  • Thomas Steyer opened 26 new positions and closed 20 in Q3 2018.
  • Thomas Steyer's portfolio value rose 4.6% quarter-over-quarter to $16.9B.

Based on Farallon Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.